Limited-stage small cell lung cancer (LS-SCLC) remains an aggressive malignancy that frequently recurs despite radical therapy. Recent data from a phase 2 clinical trial investigate the role of durvalumab in LS-SCLC when integrated directly with concurrent chemoradiotherapy (cCRT). While immunotherapy has revolutionized extensive-stage disease, its optimal timing in limited-stage settings remains a subject of intense clinical scrutiny.

Efficacy of durvalumab in LS-SCLC

In this single-arm study, 51 patients underwent a regimen of etoposide and platinum-based chemotherapy combined with durvalumab. Patients received thoracic radiotherapy concurrently with the chemoimmunotherapy cycles. Results showed a median progression-free survival (PFS) of 17.0 months. The 1-, 2-, and 3-year PFS rates were 56.9%, 35.9%, and 28.2%, respectively. Furthermore, the median overall survival (OS) reached 32.0 months. These survival outcomes suggest that adding durvalumab during the radiation phase is feasible and provides encouraging efficacy.

Safety and Tolerability

Safety is a primary concern when combining thoracic radiation with PD-L1 inhibitors. In this trial, 33.4% of patients experienced grade 3 or 4 adverse events. Specifically, seven cases involved immune-related events. However, the cohort generally tolerated the treatment well. Consequently, these findings support the continued investigation of concurrent immunotherapy in patients eligible for radical chemoradiotherapy.

Clinical Context and Future Directions

This trial adds to the growing body of evidence regarding immune checkpoint inhibitors in LS-SCLC. While the landmark ADRIATIC trial established durvalumab as a standard for consolidation therapy, the concurrent approach tested here aims to maximize the synergistic effects of radiation and immunotherapy. Moreover, physicians should monitor for potential pulmonary toxicity, although current results are promising.

Frequently Asked Questions

What were the survival rates observed in the trial?

The study reported 3-year progression-free survival (PFS) and overall survival (OS) rates of 28.2% and 49.6%, respectively, with a median OS of 32.0 months.

How safe was the combination of durvalumab and concurrent radiation?

The treatment was well tolerated. Approximately 33.4% of patients experienced grade 3 or 4 adverse events, but immune-related toxicities were manageable with standard care.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Song C et al. Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial. Cancer. 2026 Mar 15. doi: 10.1002/cncr.70351. PMID: 41832629.


2. Senan S et al. Durvalumab as consolidation treatment in limited-stage small-cell lung cancer. N Engl J Med. 2025;391(11):1020-1031.


3. Higgins KA et al. NRG Oncology/Alliance LU005: Atezolizumab with concurrent chemoradiation for limited-stage small cell lung cancer. J Clin Oncol. 2024;42(17_suppl):LBA02.